The Promising Role of PKM2 in the Diagnosis and Prognosis of Ovarian Cancer.

Abstract

PKM2 has emerged as a critical biomarker with the potential to enhance both diagnostic accuracy and therapeutic strategies in ovarian cancer. Due to its high fatality rate and difficulty identifying early signs, ovarian cancer remains a major global health concern. Biomarkers, particularly PKM2, provide targeted therapeutic methods and early detection. The complex role of PKM2 in cancer metabolism highlights its importance as a diagnostic biomarker, particularly through its involvement in the Warburg effect. Its interaction with key signaling pathways and tissue-specific expression patterns makes it a compelling target for personalized therapeutic strategies. Moreover, the detection of PKM2 in the blood of cancer patients further underscores its clinical utility and therapeutic relevance. Beyond diagnostics, PKM2 is also a promising therapeutic target. Preclinical research has reported that both activators and inhibitors of this protein are effective. For PKM2-based treatments to be successfully incorporated into clinical practice, extensive research and rigorous validation are required. To overcome the difficulties in managing ovarian cancer and accomplish the objective of improved early detection and individualised treatment methods, collaboration among the research, healthcare, and advocacy sectors is crucial. In conclusion, PKM2 represents a promising target in the fight against ovarian cancer, with the potential to improve diagnostic accuracy, therapeutic strategies, and overall patient survival.